Researchers discover protein that may be associated with better prognosis for women with ovarian cancer

Cancer Research Communication (2022). DOI: 10.1158/2767-9764.CRC-22-0122″ width=”653″ height=”530″/>

ARID1A loss correlates negatively with the prognosis of OCCC patients. a. Top, representative images of ARID1A negative or positive clinical OCCC samples and their respective H&E staining (bottom). b. Frequency distribution of the immunoreactivity scores for ARID1A; the dotted line represents the boundary used to distinguish between ARID1A-positive (+) and ARID1A-negative (-) patients. c. Survival curves of ARID1A+ vs ARID1A- patients expressed in years. From left to right: progression-free survival, PFS (36 vs 19; P=0.046; hazard ratio, HR=0.43; 95% confidence interval, CI 0.19 to 0.98), cancer-specific survival, CSS (36 vs 18; P=0.003, HR=0.18, 95% CI 0.06 to 0.55), Overall Survival, OS (36 vs 19; P=0.004; HR=0.23, 95% CI 0.09, 0, 63). Credit: Communication about cancer research (2022). DOI: 10.1158/2767-9764.CRC-22-0122

Researchers at the University of Minnesota have found that a protein associated with metabolism, previously recognized as a potential therapeutic target for ovarian cancer, may instead be associated with a better prognosis for women with this cancer.

Published in Communication about cancer research, researchers from the U of M Medical School and the Masonic Cancer Center focused on GLS1, a protein that plays a key role in the metabolism of the nutrient glutamine used as an energy source in several cancers. Using tumor samples from patients with a specific subtype of ovarian cancer known as clear cell carcinoma, the researchers found that an abundance of GLS1 did not correlate with a gene mutation found in up to 60% of clear cell ovarian cancer cases, as previously thought. .

“This study provides an example of the usefulness of clinical tumor specimens from human patients for confirming preliminary results that identify potential drug targets,” said Martina Bazzaro, Ph.D., an associate professor at the Medical School, Masonic Cancer Center, and a researcher. of the study’s senior authors.

The research is especially timely because a drug that blocks GLS1 was recently evaluated in a clinical trial for patients with ovarian cancer, and those patients developed resistance to standard-treatment chemotherapy. The current study provides evidence that this approach is potentially harmful due to the protective effect of GLS1.

Emil Lou, MD, Ph.D., FACP, an associate professor at the Medical School, Masonic Cancer Center, and a senior author of the study, said, “Expression of any drug target can vary from tumor to tumor. our finding that GLS1 is protective and associated with better patient outcomes, which is reason to interrupt any consideration of therapeutic targeting of GLS1, as neutralization would block its protective effect and potentially be harmful to patients.”

The clinical trial for ovarian cancer patients targeting GLS1 in combination with another drug was discontinued in the spring of 2022, and the results of the current study may serve as the basis for further research into the true role of this protein in ovarian cancer and why it is used. may be associated with a better prognosis in patients at the molecular level.

Link between ovarian cancer driver and metabolism opens new therapeutic strategies

More information:
Valentino Clemente et al, GLS1 is a protective factor in patients with ovarian clear cell carcinoma and its expression does not correlate with ARID1A mutated tumors, Communication about cancer research (2022). DOI: 10.1158/2767-9764.CRC-22-0122

Provided by the University of Minnesota

Quote: Researchers discover protein potentially associated with better prognosis for women with ovarian cancer (2022, July 20) retrieved July 20, 2022 from cancer .html

This document is copyrighted. Other than fair dealing for personal study or research, nothing may be reproduced without written permission. The content is provided for informational purposes only.

Leave a Comment